Lexicon Pharmaceuticals, Inc.(LXRX)

Description: Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has completed two Phase II clinical trials for the treatment of type 1 and type 2 diabetes; LX1032, which is in Phase III clinical trials for the treatment of carcinoid syndrome and ulcerative colitis; and LX1033 that is in Phase II clinical trials for the treatment of irritable bowel syndrome. The company is also developing LX2931 that has completed Phase II clinical trials for the treatment of rheumatoid arthritis; and LX7101, which is in Phase I clinical trials for the treatment of glaucoma. It has drug discovery and development collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; Schering-Plough/Organon; and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

---

Keywords: Biopharmaceutical Life Sciences Diabetes Drug Discovery Monoclonal Antibodies Clinical Trial Rheumatoid Arthritis Clinical Development Glaucoma Ulcer Ulcerative Colitis Colitis Human Diseases Irritable Bowel Syndrome Takeda Pharmaceutical Company The Woodlands Treatment Of Glaucoma Biotie Therapies Carcinoid Syndrome Treatment Of Irritable Bowel Syndrome

---

Home Page: www.lexpharma.com

LXRX Technical Analysis

2445 Technology Forest Boulevard
The Woodlands, TX 77381
United States
Phone: 281 863 3000

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)